chinese t2d patients who are inadequate controlled (6.5 %< hba1c ≤9%) by metformin (≥750mg/d but ≤1000mg/d, ≥12 weeks),

type 1 diabetes and secondary diabetes

acute metabolic diabetic complications within the past 3 months.

acute infections which may influence glucose level.

evidence of significant chronic diabetic complications,

clinically significant renal impairment and hepatic impairment patients, including history of cirrhosis or chronic hepatitis,

fpg > 270 mg/dl (15 mmol/l)

any of the following disease within the past 6 months: myocardial infarction (mi); coronary artery bypass surgery or percutaneous coronary intervention; unstable angina or stroke; congestive heart failure (chf)

other protocol-defined inclusion/exclusion criteria may apply